<!DOCTYPE html>
<html>
    <head>
        <title>US-SXR-CNS-Tolerability</title>
        <meta charset="UTF-8">
        <meta name="format-detection" content="telephone=no" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no">
        <link rel='stylesheet' href='../shared/assets/css/style.css' />
        <link rel='stylesheet' href='../shared/assets/css/reveal.css' />
        <link rel='stylesheet' href='../shared/assets/css/footer.css' />

        <script type="text/javascript" src="../shared/assets/js/jquery-1.11.1.min.js"></script>

    </head>
    <body id="Tolerability" class="template-2 tolerability tolerability-mdd tolerability-bpd">

        <div id="discussionQuestion"></div>

        <div id="st-container" class="st-container st-effect-9">

            <div class='s-navbar st-menu st-effect-9' >
    <a id="switch" href="#" title="" class="btn-switch">
      <span class="bpd switch_title">BP DISORDER</span>
      <span class="mdd switch_title">MDD</span>
    </a>
    <ul>
        <li><a id='so-0' href='#' data-nav="true"><span class='clock'></span></a></li>
        <li><a id='so-1' href='#' data-nav="true"><span class='weight'></span></a></li>
        <li><a id='so-2' href='#' data-nav="true"><span class='chart'></span></a></li>
        <li><a id='so-3' href='#' data-nav="true"><span class='pill'></span></a></li>
        <li><a id='so-4' href='#' data-nav="true"><span class='isi'></span></a></li>
        <li><a id='so-5' href='#' data-nav="true"><span class='briefcase'></span></a></li>
        <li><a id='so-6' href='#' data-nav="true"><span class='wallet'></span></a></li>
        <li><a id='so-7' href='#' data-nav="true"><span class='ind'></span></a></li>
        <li><a id='so-8' href='#' data-nav="true"><span class='envelope'></span></a></li>
    </ul>
</div>
<script type="text/javascript">
    $(document).ready(function(e) {
        $('.s-navbar ul li a').on('click', function(e) {
            e.preventDefault();
            window.location.href = $(this).attr('href');
        });
    });
</script>

<div class='st-pusher'>
                <div id="s-page" class='s-content'>
                    <div id="st-trigger-effects" class="column">
                        <button data-effect="st-effect-9" class='s-logo'></button>
                    </div>

                    <style>
    #isi_x_a .patient-popup .btn-close, .x, .close-x {
        display: block;
        position: absolute;
        width: 22px;
        height: 22px;
        background-repeat: no-repeat;
        background-position: 0px -468px;
        background-image:url('assets/_global/img/sprite.png')
        top: -45px;
        margin-left: 490px;



    }
    #isi_x {
        width: 23px;
        height: 23px;
    }
    .ISI_title_popup { font-size: 19px; }

  

</style>


<div id='patient-popup-ISI' class='patient-popup pp-1' style="">
<a id="isi_x_a" href='#' title='close' class='btn-close'></a>


    <div class='content scrollable'>
        <b class="ISI_title_popup">Important Safety Information About SEROQUEL XR&reg; (quetiapine fumarate)</b>
        <p>
            <b>
            Increased Mortality in Elderly Patients with Dementia-Related Psychosis:<br />
            Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of
            death. SEROQUEL XR is not approved for the treatment of patients with dementia-related psychosis.
            </b>
        </p>
        <p>
            <b>
            Suicidal Thoughts and Behavior:<br />
            Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. SEROQUEL XR is not approved for use in pediatric patients under ten years of age.
            </b>
        </p>
        <p>
        <b>Contraindication</b><br />
        Hypersensitivity to quetiapine or to any excipients in the SEROQUEL XR formulation. Anaphylactic reactions have been reported in patients treated with SEROQUEL XR.
        </p>
        <p>
            <b>Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis:</b><br />
            In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, 
            there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks), 
            including fatalities, compared to placebo-treated subjects. 
            <br>SEROQUEL XR is not approved for the treatment of patients with 
            dementia-related psychosis.
        </p>
        <p>
            <b>Neuroleptic Malignant Syndrome (NMS): </b>A potentially fatal symptom complex, sometimes referred to as NMS, has been reported in association with administration of antipsychotic drugs, including SEROQUEL XR. Rare cases of NMS have been reported with SEROQUEL XR. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Management should include immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptomatic treatment, and medical monitoring, and treatment of any concomitant serious medical problems.
        </p>
        <p>
            <b>Metabolic Changes:</b> <br> Atypical antipsychotic drugs have been associated with metabolic changes that include hyperglycemia/diabetes mellitus, dyslipidemia, and body weight gain. In some patients, a worsening of more than one of the metabolic parameters of weight, blood glucose, and lipids was observed in clinical studies. Changes in these metabolic profiles should be managed as
            clinically appropriate.
        </p>
        <ul class="ISI_indent">
            <li>
                <b><i>Hyperglycemia and Diabetes Mellitus:</i></b> Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma, or death, has been reported in patients treated with atypical antipsychotics, including SEROQUEL XR. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatment-emergent, hyperglycemia-related adverse reactions in patients treated with atypical antipsychotics. Patients starting treatment with atypical antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug.
            </li>
            <li>
                <b><i>Dyslipidemia:</i></b> Undesirable alterations in lipids have been observed with SEROQUEL XR use. Increases in total cholesterol, LDL-cholesterol and triglycerides, and decreases in HDL-cholesterol have been reported in clinical trials. Appropriate clinical monitoring is recommended, including fasting blood lipid testing at the beginning of and periodically during treatment.
            </li>
            <li>
                <b><i>Weight Gain:</i></b> Increases in weight have been observed in clinical trials. Patients receiving <br>SEROQUEL XR should receive regular monitoring of weight.
            </li>
        </ul>
        <p>
            <b>Tardive Dyskinesia (TD):</b> TD, a potentially irreversible syndrome of involuntary dyskinetic movements, may develop in patients treated with antipsychotic drugs. The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and total cumulative dose of antipsychotic drugs administered to the patient increase. Although much less commonly, TD can develop after relatively brief treatment periods at low doses or even after treatment discontinuation. TD may remit, partially or completely, if antipsychotic treatment is withdrawn. SEROQUEL XR should be prescribed in a manner that is most likely to minimize the occurrence of TD, and discontinuation should be considered if signs and symptoms of TD occur.
        </p>
        <p>
            <b>Hypotension:</b> SEROQUEL XR may induce orthostatic hypotension with associated dizziness, tachycardia, and syncope, especially during the initial dose titration period and should be used with caution in patients predisposed to hypotension or with known cardiovascular or cerebrovascular disease.
        </p>
        <p>
            <b>Leukopenia, Neutropenia, and Agranulocytosis:</b> Leukopenia, neutropenia, and agranulocytosis (including fatal cases), have been reported temporally related to atypical antipsychotics, including SEROQUEL XR. Patients with a pre-existing low white blood cell (WBC) count or a history of drug-induced leukopenia/neutropenia should have their complete blood count monitored frequently during the first few months of therapy. In these patients, SEROQUEL XR should be discontinued at the first sign of a decline in WBC absent other causative factors. Patients with neutropenia should be carefully monitored, and SEROQUEL XR should be discontinued in any patient if the absolute neutrophil count is <1000/mm<sup>3</sup>.
        </p>
        <p>
            <b>Cataracts:</b> Examination of the lens by methods adequate to detect cataract formation, such as slit lamp exam or other appropriately sensitive methods, is recommended at initiation of treatment or shortly thereafter, and at 6-month intervals during chronic treatment.
        </p>
        <p>
            <b>QT Prolongation:</b> Postmarketing cases show increases in QT interval in patients who overdosed on quetiapine, in patients with concomitant illness, and in patients taking medicines known to cause electrolyte imbalance or increase the QT interval. Avoid use with drugs that increase the QT interval and in patients with risk factors for prolonged QT interval.
        </p>
        <p>
            <b>Seizures:</b> SEROQUEL XR should be used cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold (eg, Alzheimer&rsquo;s dementia).
        </p>
        <p>
            <b>Potential for Cognitive and Motor Impairment:</b> Since SEROQUEL XR has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about performing activities requiring mental alertness, such as operating a motor vehicle or operating hazardous machinery, until they are reasonably certain that SEROQUEL XR therapy does not affect them adversely.
        </p>
        <p>
            <b>Body Temperature Regulation:</b> Disruption of the body&rsquo;s ability to reduce core body temperature has been attributed to antipsychotics. Appropriate care is advised for patients who may exercise strenuously, be exposed to extreme heat, receive concomitant medication with anticholinergic activity, or be subject to dehydration.
        </p>
        <p>
            <b>Dysphagia:</b> Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Use caution in patients at risk for aspiration pneumonia. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer&rsquo;s dementia.
        </p>
        <p>
            <b>Warnings and Precautions Also Include:</b> The risk of hypothyroidism, hyperprolactinemia, and discontinuation syndrome.
        </p>
        <p>
            <b>Common Adverse Reactions:</b> The most commonly observed adverse reactions (incidence &ge;5% and twice placebo) associated with the use of SEROQUEL XR versus placebo in clinical trials for all adult indications were somnolence (25%-52% vs 9%-13%), dry mouth (12%-40% vs 1%-8%), constipation (6%-11% vs 3%-6%), dizziness (10%-13% vs 4%-11%), increased appetite (2%-12% vs 0%-6%), dyspepsia (2%-7% vs 1%-4%), weight gain (3%-7% vs 0%-1%), fatigue (3%-14% vs 2%-4%), dysarthria (2%-5% vs 0%), and nasal congestion (2%-5% vs 1%).
        </p>
        <p>
            <i><b>Please read <a href="US-SXR-CNS-PI" data-nav="true">Prescribing Information</a>, including Boxed WARNINGS.</b></i>
        </p>
        <p>
            <i>You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <a id="external_link" target="_blank" href="http://www.fda.gov/medwatch" style="text-decoration: none;"><u>www.FDA.gov/medwatch</u></a> or call 1-800-FDA-1088.</i>
        </p>
        <p>
            The product information is intended for US health care professionals only.
        </p>
        <p>
            SEROQUEL XR is a registered trademark of the AstraZeneca group of companies.<br />
            &copy;2015 AstraZeneca. All rights reserved. 3086417 Last Updated 2/15
        </p>

    </div>
</div>

<div id='page-overlay' class='page-overlay'></div>

                    
<div id='patient-popup-1' class='patient-popup pp-1'><!-- POPUP FOR  SOMNOLENCE MDD-->
        <div class='content'>
            <a href='#' title='close' class='btn-close'></a>
            <span class="popup_header">References</span>
            <ol>
                <li><span>Prescribing Information for SEROQUEL XR. AstraZeneca Pharmaceuticals LP, Wilmington, DE.</span></li>
                <li><span>Data on file, 3092201, AstraZeneca Pharmaceuticals LP.</span></li>
            </ol>
        </div>
    </div>

    <div id='patient-popup-2' class='patient-popup pp-1'><!-- POPUP FOR  WEIGHT MDD-->
        <div class='content'>
            <a href='#' title='close' class='btn-close'></a>
            <span class="popup_header">References</span>
            <ol>
                <li><span>Bauer M, El-Khalili N, Datto C, Szamosi J, Eriksson H. A
                    <br />pooled analysis of two randomised, placebo-controlled
                    <br />studies of extended release quetiapine fumarate adjunctive
                    <br />to antidepressant therapy in patients with major depressive
                    disorder. <i>J Affect Disord</i>. 2010;127:19-30.</span></li>
                <li><span>Data on file, 2352501, AstraZeneca Pharmaceuticals LP.</span></li>
                <li><span>Data on file, 272709, AstraZeneca Pharmaceuticals LP.</span></li>
                <li><span>Prescribing Information for SEROQUEL XR. AstraZeneca
                    <br />Pharmaceuticals LP, Wilmington, DE.</span></li>
            </ol>
        </div>
    </div>

    <div id='patient-popup-3' class='patient-popup pp-1'><!-- POPUP FOR  EPS MDD-->
        <div class='content'>
            <a href='#' title='close' class='btn-close'></a>
            <span class="popup_header">References</span>
            <ol>
                <li><span>Prescribing Information for SEROQUEL XR. AstraZeneca
                    <br />Pharmaceuticals LP, Wilmington, DE.</span></li>

                <li><span>Bauer M, El-Khalili N, Datto C, Szamosi J, Eriksson H. A
                    <br />pooled analysis of two randomised, placebo-controlled
                    <br />studies of extended release quetiapine fumarate adjunctive
                    <br />to antidepressant therapy in patients with major depressive
                    <br />disorder. <i>J Affect Disord</i>. 2010;127:19-30.</span></li>

                <li><span>Data on file, 272709, AstraZeneca Pharmaceuticals LP.</span></li>
            </ol>
        </div>
    </div>

    <div id='patient-popup-4' class='patient-popup pp-1'><!-- POPUP FOR  BPD SOMNOLENCE Section1-->
        <div class='content'>
            <a href='#' title='close' class='btn-close'></a>
            <span class="popup_header">References</span>
            <ol>
                <li><span>Prescribing Information for SEROQUEL XR. AstraZeneca<br> Pharmaceuticals LP, Wilmington, DE.</span></li>
                <li><span>Data on File, 2371602, AstraZeneca Pharmaceutical LP.</span></li>
                <li><span>Data on File, 3092208, AstraZeneca Pharmaceuticals LP.</span></li>
            </ol>
        </div>
    </div>

    <div id='patient-popup-5' class='patient-popup pp-1'><!-- POPUP FOR BPD SOMNOLENCE Section2-->
        <div class='content'>
            <a href='#' title='close' class='btn-close'></a>
            <span class="popup_header">References</span>
            <ol>
                <li><span>Prescribing Information for SEROQUEL XR. AstraZeneca <br>Pharmaceuticals LP, Wilmington, DE.</span></li>
                <li><span>Data on file, 274340, AstraZeneca Pharmaceuticals LP.</span></li>
                <li><span>Data on file, 3092208, AstraZeneca Pharmaceuticals LP.</span></li>
                <li><span>Datto C, Berggren L, Patel JB, et al. Self-reported sedation profile of
                    immediate-release quetiapine fumarate compared with
                    extended-release quetiapine fumarate during dose initiation: a
                    randomized, double-blind crossover study in healthy adult
                    subjects. <i>J Clin Ther.</i> 2009;31(3):492-502.</span></li>
                <li><span>Data on file, 2796900, AstraZeneca Pharmaceuticals LP.</span></li>
            </ol>
        </div>
    </div>

    <div id='patient-popup-6' class='up-6 patient-popup pp-1'><!-- POPUP FOR BPD 9.0_BPD_WeightGain_REFS-->
        <div class='content'>
            <a href='#' title='close' id="up-6-close" class='btn-close'></a>
            <span class="popup_header">References</span>
            <ol>
                <li><span>Suppes T, Datto C, Minkwitz M, et al. Corrigendum to
                    <br />“Effectiveness of the extended release formulation of quetiapine
                    <br />as monotherapy for the treatment of acute  bipolar depression”
                    <br />[<i>J Affect Disord</i>. 121 (1-2) (2010)   106-115]. <i>J Affect Disord</i>.
                    <br />2014;168:485-493.</span></li>
                <li><span>Data on file, 2352501, AstraZeneca Pharmaceuticals LP.</span></li>
                <li><span>Data on file, 3092208, AstraZeneca Pharmaceuticals LP.</span></li>
                <li><span>Prescribing Information for SEROQUEL XR. AstraZeneca
                    <br>Pharmaceuticals LP, Wilmington, DE.</span></li>
            </ol>
        </div>
    </div>

    <div id='patient-popup-7' style='width: 550px' class='patient-popup pp-1'><!-- POPUP FOR BPD 9.0_BPD_WeightGain_ShortTerm_REFS-->
        <div class='content'>
            <a href='#' title='close' class='btn-close'></a>
            <span class="popup_header">References</span>
            <ol>
                <li><span>Prescribing Information for SEROQUEL XR. AstraZeneca
                    <br /> Pharmaceuticals LP, Wilmington, DE.</span></li>
                <li><span>Data on file, 2352501, AstraZeneca Pharmaceuticals LP.</span></li>
                <li><span>Suppes T, Datto C, Minkwitz M, et al. Corrigendum to
                    <br />“Effectiveness of the extended release formulation of quetiapine as
                    <br />monotherapy for the treatment of acute       bipolar depression” [<i>J Affect
                    <br />Disord</i>. 121 (1-2) (2010)106-115].      <i>J Affect Disord</i>. 2014;168:485-493.</span></li>
                <li><span>Data on file, 265022, AstraZeneca Pharmaceuticals LP.</span></li>
                <li><span>Cutler AJ, Datto C, Nordenhem A, et al. Extended-release
                    <br />quetiapine as monotherapy for the treatment of adults with acute
                    <br />mania: A randomized, double-blind, 3-week trial.          <i>Clin Ther</i>.
                    <br />2011;33(11):1643-1658.</span></li>
            </ol>
        </div>
    </div>

    <div id='patient-popup-8' class='patient-popup pp-1' style='word-wrap: break-word;'><!-- POPUP FOR BPD 9.0_BPD_WeightChange_LBS_REFS-->
        <div class='content'>
            <a href='#' title='close' class='btn-close'></a>
            <span class="popup_header">References</span>
            <ol>
                <li><span>Data on file, 2352501, AstraZeneca Pharmaceuticals LP.</span></li>
                <li><span>Prescribing Information for SEROQUEL XR. AstraZeneca <br />  Pharmaceuticals LP, Wilmington, DE.</span></li>
                <li><span>Classification of overweight and obesity by BMI, waist
                    <br />circumference, and associated disease risks. National Heart,
                    <br />Lung, and Blood Institute.
                    <br />http://www.nhlbi.nih.gov/health/public/heart/obesity/lose_wt/bmi_dis.htm. Accessed February 5, 2015.</span></li>
                <li><span>Data on file, 265022, AstraZeneca Pharmaceuticals LP.</span></li>

            </ol>
        </div>
    </div>

    <div id='patient-popup-9' class='patient-popup pp-1'><!-- POPUP FOR BPD 9.0_EPS_BPD_REF - page 1-->
        <div class='content'>
            <a href='#' title='close' class='btn-close'></a>
            <span class="popup_header">References</span>
            <ol>
                <li><span>Prescribing Information for SEROQUEL XR. AstraZeneca
                    <br /> Pharmaceuticals LP, Wilmington, DE.</span></li>
                <li><span>Suppes T, Datto C, Minkwitz M, et al. Corrigendum to
                    <br />“Effectiveness of the extended release formulation of
                    <br />quetiapine as monotherapy for the treatment of acute bipolar
                    <br />depression” [J Affect Disord. 121 (1-2) (2010)106-115].
                    <br />J Affect Disord. 2014;168:485-493.</span></li>
                <li><span>Data on file, 3092208, AstraZeneca Pharmaceuticals LP. </span></li>

            </ol>
        </div>
    </div>

    <div id='patient-popup-10' class='patient-popup pp-1'><!-- POPUP FOR BPD 9.0_EPS_BPD_REF - page 2-->
        <div class='content'>
            <a href='#' title='close' class='btn-close'></a>
            <span class="popup_header">Reference</span>
            <ol>
                <li><span>Prescribing Information for SEROQUEL XR. AstraZeneca
                    <br /> Pharmaceuticals LP, Wilmington, DE.</span></li>

            </ol>
        </div>
    </div>
    <!-- end popup area -->

    <a href='#' class='btn-people' title=''><img src='../shared/assets/img/PatienProfile/img/icon-people.png' /></a>

<div class="content">
    <h4 id='title-gray'>SEROQUEL XR Tolerability</h4>
    <h1 id='title-page'>Adverse reactions observed in the bipolar depression trial with SEROQUEL XR*</h1>

    <div class='navbar-tabs-container'>
        <ul id='bpd-navbar' class='navbar-tabs'>
            <li><a id='tab-bpd-1' href='#/mdd-1' title='BPD' rel='1' class="bpd-button">BP Disorder</a></li>
            <li><a id='tbpd-1' href='#/bpd-1' rel="0" title='Somnolence' class='active'>Somnolence</a></li>
            <li><a id='tbpd-2' href='#/bpd-2' rel="1" title='Weight Gain'>Weight Gain</a></li>
            <li><a id='tbpd-3' href='#/bpd-3' rel="2" title='EPS'>EPS</a></li>
        </ul>

        <ul id='mdd-navbar' class='navbar-tabs hidden'>
            <li><a id='tab-mdd-1' class='mdd-button' href='#/bpd-1' title='MDD' rel='1'>MDD</a></li>
            <li><a id='tmdd-1' href='#/mdd-1' title='Somnolence' rel="3">Somnolence</a></li>
            <li><a id='tmdd-2' href='#/mdd-2' title='Weight Gain' rel="4">Weight Gain</a></li>
            <li><a id='tmdd-3' href='#/mdd-3' title='EPS' rel="5">EPS</a></li>
        </ul>
    </div><!-- end navbar-tabs-container -->

    <div class='tabs-container'>
        <div id="tabs-bpd" class="reveal">
            <div class="slides">
                <section id='bpd-1' data-transition="slide">
                    <section data-transition="slide" class="slide-1">
                        <h3>Somnolence<sup>†</sup>
                            <span class="tiny-title">Percent of patients with bipolar depression who reported an adverse event of somnolence<sup>&dagger;</sup></span>
                        </h3>
                        <br>
                        <div  class="chart-content">
                            <ul class="list-content" >
                                <li>
                                    <div class="mdd-chart-legend bpd-legend-1">Reported
                                        somnolence<sup>†</sup>
                                        <h3>52%</h3></div>
                                    <div class="mdd-chart-legend bpd-legend-2">Did not report
                                        somnolence<sup>†</sup>
                                        <h3>48%</h3></div>
                                    <div id="pieChart-bpd-1" class="pie-chart bpd-chart-1"></div>
                                    <div class="text-aling-bpd">
                                        <h4>SEROQUEL XR 300 mg/day (n=137)</h4>
                                        <table class="chart-table">
                                            <tr>
                                                <td class="line-5">*</td>
                                                <td class="text-bpd-section">Data from an 8-week, multicenter, randomized,<br>
                                            double-blind, parallel-group, placebo-controlled<br>
                                            monotherapy trial in the treatment of patients with <br>
                                            depressive episodes associated with bipolar I or II disorder.</td>
                                            </tr>
                                        </table>
                                    </div>
                                </li>

                                <li class="second-column">
                                    <div class="mdd-chart-legend bpd-legend-3">Reported
                                        somnolence<sup>†</sup>
                                        <h3>13%</h3></div>
                                    <div class="mdd-chart-legend bpd-legend-4">Did not report
                                        somnolence<sup>†</sup>
                                        <h3>87%</h3></div>
                                    <div id="pieChart-bpd-2" class="pie-chart bpd-chart-2"></div>
                                    <div class="text-aling-bpd">
                                        <h4>Placebo  (n=140)</h4>
                                        <table class="chart-table">
                                            <tr>
                                                <td class="line-5"><sup>&dagger;</sup></td>
                                                <td class="text-bpd-section">Somnolence includes the adverse reaction <br>
                                            terms “somnolence” and “sedation.”</td>
                                            </tr>

                                            <tr>
                                                <td class=" line-5"><sup>‡</sup></td>
                                                <td class="text-bpd-section">Somnolence duration was for the cumulative incidence of somnolence and sedation.</td>
                                            </tr>
                                        </table>
                                    </div>
                                </li>

                                <li class="third-column">
                                    <ul class="pink-bullet list-big">
                                        <li> In an 8-week clinical trial, 52%
                                            <br /> of patients taking SEROQUEL XR
                                            <br />reported incidence of<br />
                                            somnolence<sup>†</sup> vs 13% for placebo<sup>1</sup></li>

                                        <li>Median duration of somnolence<sup>†</sup>
                                            <br />  reported for SEROQUEL XR was 10 days<sup>‡2</sup></li>

                                        <li>10.2% of patients discontinued
                                            <br />due to somnolence<sup>†</sup> vs 0% on
                                            <br /> placebo.<sup>1,3</sup> A majority of these
                                            <br />patients (13/14) discontinued
                                            <br />within the first three weeks<sup>3</sup>
                                        </li>
                                    </ul>

                                </li>
                            </ul>
                        </div>
                    </section>

                    <section data-transition="slide" class="slide-2">
                        <h3>Incidence of somnolence<sup class="smaller_sup_1">*</sup> adverse events in bipolar disorder trials<sup class="smaller_sup_1">1-3</sup></h3>
                        <p>&nbsp;</p>
                        <ul class="bpd-section-2">
                            <li>
                                <table class="bpd-table bpd-table-1">
                                    <tr>
                                        <th colspan="2" class="rounded-left-top gray-soft">Bipolar Depression<sup>a</sup></th>
                                        <th colspan="2" class="rounded-right-top">Bipolar Mania<sup>b</sup></th>
                                    </tr>

                                    <tr>
                                        <td>Placebo (n)</td>
                                        <td class="cell-pink">SEROQUEL XR<br /><span class="chart_smaller">300 mg/day (n)</span></td>
                                        <td>Placebo (n)</td>
                                        <td  class="cell-pink">SEROQUEL XR<br /><span class="chart_smaller">400 mg-800 mg/day (n)</span></td>
                                    </tr>

                                    <tr>
                                        <td class="rounded-left-bottom">13% (18/140)</td>
                                        <td class="cell-pink2">52% (71/137)</td>
                                        <td>12% (19/160)</td>
                                        <td class="rounded-right-bottom cell-pink2">50% (76/151)</td>
                                    </tr>
                                </table>
                                <p class="txt-black">*Somnolence combines adverse reaction terms "somnolence" and<br /> "sedation."</p>
                                <table class="footer-notes">
                                    <tr>
                                        <td><sup>a</sup></td>
                                        <td>Data from an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled
                                    <br /> monotherapy trial in the treatment of patients with depressive episodes associated with bipolar I
                                    <br /> or II disorder.</td>
                                    </tr>

                                    <tr>
                                        <td><sup>b</sup></td>
                                        <td>Data from a 3-week, multicenter, randomized, double-blind, placebo-controlled monotherapy
                                    <br />trial in the treatment of patients with manic or mixed episodes associated with bipolar I disorder.
                                    <br />Flexible dosing from 400 mg/day to 800 mg/day. The mean dose was 604 mg/day.
                                        <p>&nbsp;</p>
                                        </td>
                                    </tr>
                                </table>
                                <ul class="list-square-pink">
                                    <li >Discontinuation rates due to somnolence* in patients with bipolar
                                        <br />depression were 10.2% with SEROQUEL XR vs 0.0% with
                                        <br /> placebo; in patients with bipolar mania, the rates were 0.0% for
                                        <br />SEROQUEL XR and 0.6% with placebo<sup class="smaller-sup">2,3</sup>
                                    </li>
                                </ul>

                            </li>

                            <li>
                                <ul class="list-square-pink">
                                    <li>
                                        A clinical study of SEROQUEL XR in healthy volunteers (n=58)
                                        <br /> evaluated the intensity of somnolence postdose during the initial
                                        <br /> titration period from Day 1 (50 mg) to Day 4 (300 mg). Intensity of
                                        <br />somnolence was measured by using a 100-mm Visual Analog Scale
                                        <br /> (VAS),<sup class="smaller-sup">&dagger;</sup> with responses ranging from alert (=0) to drowsy (=100); if a
                                        <br />  subject was asleep, a score of 100 was assigned.<sup class="smaller-sup">4,5</sup>

                                        <ul class="list-square-black">
                                            <li>Highest mean VAS scores ranged from 52.2-54.9 across <br />doses during the 4-day titration period<sup class="smaller-sup">5</sup> </li>
                                            <li>The highest mean VAS scores were reported between <br />3 and 8 hours postdose<sup class="smaller-sup">5</sup></li>
                                        </ul>
                                    </li>
                                </ul>

                                <p>
                                    <b>Potential for Cognitive and Motor Impairment:</b> Somnolence was a<br />
                                    commonly reported adverse event reported in patients treated with <br />
                                    quetiapine, especially during the period of initial dose titration. Since<br />
                                    SEROQUEL XR has the potential to impair judgment, thinking, or motor<br />
                                    skills, patients should be cautioned about performing activities requiring<br />
                                    mental alertness, such as operating a motor vehicle or operating hazardous <br />
                                    machinery, until they are reasonably certain that SEROQUEL XR therapy<br />
                                    does not affect them adversely.<br /> <br />
                                    <sup>&dagger;</sup>VAS is a self-reported response scale, and SEROQUEL XR was dosed in<br />  the morning.</p>
                            </li>
                        </ul>
                    </section>
                </section><!-- end section bpd somnolence -->

                <section id='bpd-2' data-transition="slide">
                    <section data-transition="slide">
                        <div class="slide"><h3>Weight Gain</h3>
                                <p>&nbsp;</p>
                                <table class='footer-notes'>
                                    <tr>
                                        <td></td>
                                        <td>*Data from an 8-week, multicenter, randomized,
                                        <br />&nbsp;double-blind, parallel-group,
                                        <br />&nbsp;placebo-controlled monotherapy trial in the
                                        <br />&nbsp;treatment of patients with depressive episodes
                                        <br />&nbsp;associated with bipolar I or II disorder.
                                        <br /><sup>†</sup>Mean baseline weight was 88.8 kg (195.4 lb)
                                        <br />&nbsp;for placebo and 88.5 kg (194.7 lb) for
                                        <br />&nbsp;SEROQUEL XR.<sup>4</sup></td>
                                    </tr>
                                </table>
                            <ul class="list-weight">
                                <li>In an 8-week clinical trial, mean change in
                                    <br />weight was +2.86 lb vs -0.44 lb for placebo<sup>1,2†</sup></li>
                                <li>No patients discontinued SEROQUEL XR<br> due to weight gain<sup>1,3</sup></li>
                                <li>8% of patients taking SEROQUEL XR had a ≥7% increase in body weight vs 1% with
                                    placebo<sup>1,4</sup> </li>
                            </ul>
                        </div>
                    </section>

                    <section data-transition="slide">
                        <ul class="weight-list">
                            <li>
                                <table class="bpd-table bpd-table-2">
                                    <tr>
                                        <th colspan="3" class="rounded-left-right-top">Acute depressive episodes of bipolar disorder in adults<sup>1-3,a,b</sup></th>
                                    </tr>

                                    <tr>
                                        <td></td>
                                        <td class="w115">Placebo</td>
                                        <td class="cell-pink w115">SEROQUEL XR<br />300 mg/day</td>
                                    </tr>

                                    <tr>
                                        <td>Weight gain (≥7% of body weight)</td>
                                        <td class="w115 cell-gray2">1%<br >(n=125)</td>
                                        <td class="cell-pink2 w115">8%<br >(n=110)</td>
                                    </tr>

                                    <tr>
                                        <td class="rounded-left-bottom">Mean change in weight</td>
                                        <td class="w115 cell-gray2">-0.2 kg (-0.44 lb)<br >(n=125)</td>
                                        <td class="cell-pink2 w115 rounded-right-bottom">1.3 kg (2.86 lb)<br >(n=110)</td>
                                    </tr>
                                </table>

                                <p class="deg"><sup>a</sup>Data from an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled
                                    <br />monotherapy trial in the treatment of patients with depressive episodes associated
                                    <br />with bipolar I or bipolar II disorder.
                                    <br />
                                    <sup>b</sup>Mean baseline weight was 88.8 kg for placebo and 88.5 kg for SEROQUEL XR.</p>
                                <br>
                                <p class="textBlack"><b class="text18">Weight gain did not lead to discontinuation from the studies<sup>3,4</sup></b></p>
                                <ul class="list-square up">
                                    <li>In patients with acute bipolar depression, mean weight change ranged
                                        <br />from -0.9 kg to 2.4 kg (-1.98 lb to 5.28 lb) across BMI categories with
                                        <br />SEROQUEL XR<sup>2</sup></li>
                                    <li>In patients with acute bipolar mania, mean weight change ranged from
                                        <br />0.5 kg to 1.9 kg (1.10 lb to 4.18 lb) across BMI categories with
                                        <br />SEROQUEL XR<sup>2</sup></li>
                                </ul>
                            </li>

                            <li>
                                <table class="bpd-table bpd-table-2">
                                    <tr>
                                        <th colspan="3" class="rounded-left-right-top">Acute manic or mixed episodes of bipolar disorder in adults <sup>1,2,5,a,b</sup></th>
                                    </tr>

                                    <tr>
                                        <td></td>
                                        <td class="w115">Placebo</td>
                                        <td class="cell-pink w115">SEROQUEL XR<br />400-800 mg/day</td>
                                    </tr>

                                    <tr>
                                        <td>Weight gain (≥7% of body weight)</td>
                                        <td class="w115 cell-gray2">0%<br >(n=150)</td>
                                        <td class="cell-pink2 w115">5%<br >(n=138)</td>
                                    </tr>

                                    <tr>
                                        <td class="rounded-left-bottom">Mean change in weight</td>
                                        <td class="w115 cell-gray2">0.1 kg (0.22 lb)<br >(n=149)</td>
                                        <td class="cell-pink2 w115 rounded-right-bottom">1.3 kg (2.86 lb)<br >(n=138)</td>
                                    </tr>
                                </table>

                                <p class="deg"><sup>a</sup>Data from a 3-week, multicenter, randomized, double-blind, placebo-controlled monotherapy trial in the
                                    <br /> treatment of patients with manic or mixed episodes associated with bipolar I disorder.
                                    <br />SEROQUEL XR was flexibly dosed between 400 mg/day and 800 mg/day. The mean dose was 604 mg/day.
                                    <br />
                                    <sup>b</sup>Mean baseline weight was 90.9 kg for placebo and 91.8 kg for SEROQUEL XR.</p>
                                <br>
                                <p class="textBlack"><b class="textBlack">Weight Gain:</b> Increases in weight have been observed in clinical trials. Patients
                                    <br />receiving SEROQUEL XR should receive regular monitoring of weight.</p>
                                <ul class="list-square">
                                    <li>The proportion of patients in adult clinical trials across indications meeting weight
                                        <br /> gain criteria &ge;7% of body weight was 5%-23% for quetiapine vs 0%-7% for <br />placebo<sup>1,4</sup>
                                    </li>
                                    <li>In some patients, a worsening of more than one of the metabolic parameters of
                                        <br />weight, blood glucose, and lipids was observed in clinical studies. Changes in
                                        <br />these parameters should be managed as clinically appropriate
                                    </li>
                                </ul>
                            </li>
                        </ul>
                    </section>

                    <section data-transition="slide">
                               <table id="lbs_table" class="bpd-table bpd-table-4">
                                    <tbody>
                                        <tr>
                                            <th class="rounded-left-top" >BMI category (kg/m<sup>2</sup>)<sup>a</sup></th>
                                            <th class="" colspan="2">Mean weight change from baseline to end <br> of study in acute bipolar depression<sup>b</sup></th>
                                            <th class="rounded-right-top" colspan="2">Mean weight change from baseline to end <br> of study in acute bipolar mania<sup>c</sup></th>
                                        </tr>
                                        <tr>
                                            <td class="cell-color">&nbsp;</td>
                                            <td class="w115 cell-color">Placebo</td>
                                            <td class="cell-pink w115">SEROQUEL XR<br />
                                            300 mg/day</td>
                                            <td class="w115 cell-color">Placebo</td>
                                            <td class="cell-pink w115">SEROQUEL XR<br />
                                            400 - 800 mg/day</td>
                                        </tr>
                                        <tr>
                                            <td class="cell-color">&lt;18.5 (Underweight)</td>
                                            <td class="w115">3.96 lb (n=1)</td>
                                            <td class="cell-pink2 w115">-1.98 lb (n=1)</td>
                                            <td class="w115">2.42 lb (n=2)</td>
                                            <td class="cell-pink2 w115">NA</td>
                                        </tr>
                                        <tr>
                                            <td class=" cell-color">18.5-&lt;25 (Normal weight)</td>
                                            <td class="w115">0.88 lb (n=24)</td>
                                            <td class="cell-pink2 w115">2.86 lb (n=18)</td>
                                            <td class="w115">0.44 lb (n=35)</td>
                                            <td class="cell-pink2 w115">1.54 lb (n=34)</td>
                                        </tr>
                                        <tr>
                                            <td class="cell-color">25-&lt;30 (Overweight)</td>
                                            <td class="w115">0.22 lb (n=36)</td>
                                            <td class="cell-pink2 w115">2.64 lb (n=37)</td>
                                            <td class="w115">-0.22 lb (n=42)</td>
                                            <td class="cell-pink2 w115">3.52 lb (n=35)</td>
                                        </tr>
                                        <tr>
                                            <td class="cell-color">30-&lt;40 (Obese)</td>
                                            <td class="w115">-1.32 lb (n=50)</td>
                                            <td class="cell-pink2 w115">5.28 lb (n=37)</td>
                                            <td class="w115">0.22 lb (n=47)</td>
                                            <td class="cell-pink2 w115">4.18 lb (n=51)</td>
                                        </tr>
                                        <tr>
                                            <td class="rounded-left-bottom cell-color">≥40 (Extremely obese)</td>
                                            <td class="w115">-1.32 lb (n=13)</td>
                                            <td class="cell-pink2 w115">-1.10 lb (n=18)</td>
                                            <td class="w115">1.32 lb (n=23)</td>
                                            <td class="cell-pink2 w115 rounded-right-bottom">1.10 lb (n=18)</td>
                                        </tr>
                                    </tbody>
                                    </table>

                                    <table id="kg_table" class="bpd-table bpd-table-4">
                                    <tbody>
                                        <tr>
                                            <th class="rounded-left-top" >BMI category (kg/m<sup>2</sup>)<sup>a</sup></th>
                                            <th class="" colspan="2">Mean weight change from baseline to end <br> of study in acute bipolar depression<sup>b</sup></th>
                                            <th class="rounded-right-top" colspan="2">Mean weight change from baseline to end <br> of study in acute bipolar mania<sup>c</sup></th>
                                        </tr>
                                        <tr>
                                            <td class="cell-color">&nbsp;</td>
                                            <td class="w115 cell-color">Placebo</td>
                                            <td class="cell-pink w115">SEROQUEL XR<br />
                                            300 mg/day</td>
                                            <td class="w115 cell-color">Placebo</td>
                                            <td class="cell-pink w115">SEROQUEL XR<br />
                                            400 - 800 mg/day</td>
                                        </tr>
                                        <tr>
                                            <td class="cell-color">&lt;18.5 (Underweight)</td>
                                            <td class="w115">1.8 kg (n=1)</td>
                                            <td class="cell-pink2 w115">-0.9 kg (n=1)</td>
                                            <td class="w115">1.1 kg (n=2)</td>
                                            <td class="cell-pink2 w115">NA</td>
                                        </tr>
                                        <tr>
                                            <td class=" cell-color">18.5&lt;25 (Normal weight)</td>
                                            <td class="w115">0.4 kg (n=24)</td>
                                            <td class="cell-pink2 w115">1.3 kg (n=18)</td>
                                            <td class="w115">0.2 kg (n=35)</td>
                                            <td class="cell-pink2 w115">0.7 kg (n=34)</td>
                                        </tr>
                                        <tr>
                                            <td class="cell-color">25&lt;30 (Overweight)</td>
                                            <td class="w115">0.1 kg (n=36)</td>
                                            <td class="cell-pink2 w115">1.2 kg (n=37)</td>
                                            <td class="w115">-0.1 kg (n=42)</td>
                                            <td class="cell-pink2 w115">1.6 kg (n=35)</td>
                                        </tr>
                                        <tr>
                                            <td class="cell-color">30&lt;40 (Obese)</td>
                                            <td class="w115">-0.6 kg (n=50)</td>
                                            <td class="cell-pink2 w115">2.4 kg (n=37)</td>
                                            <td class="w115">0.1 kg (n=47)</td>
                                            <td class="cell-pink2 w115">1.9 kg (n=51)</td>
                                        </tr>
                                        <tr>
                                            <td class="rounded-left-bottom cell-color">≥40 (Extremely obese)</td>
                                            <td class="w115">-0.6 kg (n=13)</td>
                                            <td class="cell-pink2 w115">-0.5 kg (n=18)</td>
                                            <td class="w115">0.6 kg (n=23)</td>
                                            <td class="cell-pink2 w115 rounded-right-bottom">0.5 kg (n=18)</td>
                                        </tr>
                                    </tbody>
                                    </table>
                                    <img id="kglbs" src="../shared/assets/img/tolerability/WeightChangeBMIBipolarDisorderBtn.png" />

                        <ul class="weight-list">
                            <li>
                                <ul class="list-square">
                                    <li><b>Weight Gain:</b> Increases in weight have been observed in clinical trials.
                                        Patients receiving SEROQUEL XR should receive regular monitoring of weight</li>
                                    <li>The proportion of patients in adult clinical trials across indications meeting
                                        weight gain criteria &ge;7% of body weight was 5%-23% for quetiapine vs
                                        0%-7% for placebo<sup class="smaller_sup_2">2,4</sup></li>
                                    <li>In some patients, a worsening of more than one of the metabolic
                                        parameters of weight, blood glucose, and lipids was observed in clinical
                                        studies. Changes in these parameters should be managed as clinically
                                        appropriate</li>
                                </ul>
                            </li>
                            <li>
                                <table class="deg">
                                    <tr>
                                        <td>
                                            <sup>a</sup>
                                        </td>
                                        <td>
                                            BMI category based on National Heart, Lung, and Blood Institute BMI classification.<sup>3</sup>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td>
                                            <sup>b</sup>
                                        </td>
                                        <td>
                                            Data from an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled
                                            <br />monotherapy trial in the treatment of patients with depressive episodes associated with bipolar I or
                                            <br /> bipolar II disorder.
                                            <br />
                                        </td>
                                    </tr>
                                    <tr>
                                        <td>
                                            <sup>c</sup>
                                        </td>
                                        <td>
                                            Data from a 3-week, multicenter, randomized, double-blind, placebo-controlled monotherapy trial in
                                            <br />the treatment of patients with manic or mixed episodes associated with bipolar I disorder.
                                            <br />
                                            SEROQUEL XR was flexibly dosed between 400 and 800 mg/day. The mean dose was 604 mg/day.
                                        </td>
                                    </tr>
                                </table>
                            </li>
                        </ul>
                    </section>
                </section><!-- end section bpd weight gain -->

                <section id='bpd-3' data-transition="slide">
                    <section data-transition="slide">
                        <div class="slide first-slide"><h3>Extrapyramidal Symptoms (EPS)<sup>†</sup></h3>
                            <p>&nbsp;</p>

                            <table class='footer-notes'>
                                <tr>
                                    <td>*</td>
                                    <td>Data from an 8-week, multicenter, randomized,
                                        <br />double-blind, parallel-group,
                                        <br />placebo-controlled monotherapy trial in the
                                        <br />treatment of patients with depressive episodes
                                        <br />associated with bipolar I or II disorder.</td>
                                </tr>

                                <tr>
                                    <td colspan='2'>&nbsp;</td>
                                </tr>

                                <tr>
                                    <td><sup>&dagger;</sup></td>
                                    <td>Extrapyramidal symptoms include the terms:
                                        <br />muscle spasms, akathisia, cogwheel rigidity,
                                        <br />drooling, dyskinesia, extrapyramidal disorder,
                                        <br />hypertonia, hypokinesia, psychomotor
                                        <br />hyperactivity, restlessness, and tremor.</td>
                                </tr>
                            </table>

                            <ul class="list-weight">
                                <li>In an 8-week clinical trial of SEROQUEL XR
                                    <br />for bipolar depression, the incidence of EPS
                                    <br />was 4.4% for SEROQUEL XR vs 0.7% for
                                    <br />placebo<sup>1,2</sup></li>
                                <li>In this trial, no patients discontinued
                                    <br />SEROQUEL XR due to EPS<sup>2,3</sup></li>

                            </ul>
                        </div>
                    </section>

                    <section data-transition="slide">
                            <ul class="weight-list">
                                <li>
                                    <table class="bpd-table bpd-table-3">
                            <tr>
                                <th colspan="3" class="rounded-left-right-top">Percentage of patients with adverse<br />
reactions potentially associated with EPS<sup>1,a</sup></th>
                                </th>
                            </tr>

                            <tr class="td-smaller">
                                <td></td>
                                <td>Placebo <br />(n=140)</td>
                                <td class="cell-pink">SEROQUEL XR<br />300 mg/day (n=137)</td>
                            </tr>

                            <tr>
                                <td>Total EPS-related<br />
adverse reactions</td>
                                <td class=" cell-gray2 cell-space">0.7%</td>
                                <td class="cell-pink2 cell-space">4.4%</td>
                            </tr>

                            <tr>
                                <td>Dystonic event<sup>b</sup></td>
                                <td class=" cell-gray2 cell-space">0.0%</td>
                                <td class="cell-pink2 ">1.5%</td>
                            </tr>

                            <tr>
                                <td>Parkinsonism<sup>c</sup></td>
                                <td class=" cell-gray2 cell-space">0.7%</td>
                                <td class="cell-pink2 cell-space">0.7%</td>
                            </tr>

                            <tr>
                                <td>Akathisia<sup>d</sup></td>
                                <td class=" cell-gray2 cell-space">0.0%</td>
                                <td class="cell-pink2 cell-space">1.5%</td>
                            </tr>

                            <tr>
                                <td class="rounded-left-bottom">Other extrapyramidal<br />event<sup>e</sup></td>
                                <td class=" cell-gray2 cell-space">0.0%</td>
                                <td class="cell-pink2 cell-space  rounded-right-bottom">0.7%</td>
                            </tr>
                        </table>

<table class='footer-notes table-information'>
<tr>
<td class="line2"><sup>a</sup></td>
<td>Data from an 8-week, multicenter, randomized, double-blind, placebo-controlled monotherapy
<br />trial in the treatment of patients with depressive episodes associated with bipolar I or bipolar II disorder.
<br /><br />Patients with the following terms were counted in respective categories:</td>
</tr>

<tr>
<td><sup>b</sup></td>
<td>Nuchal rigidity, hypertonia, dystonia, muscle rigidity, oculogyration.</td>
</tr>

<tr>
<td><sup>c</sup></td>
<td>Cogwheel rigidity, tremor, drooling, hypokinesia.</td>
</tr>

<tr>
<td><sup>d</sup></td>
<td>Akathisia, psychomotor agitation.</td>
</tr>

<tr>
<td><sup>e</sup></td>
<td>Restlessness, extrapyramidal disorder, movement disorder.</td>
</tr>
</table>
                                </li>

                                <li>
                                    <ul class="list-square list-regular">
                                        <li><b>Tardive Dyskinesia (TD):</b> TD, a potentially irreversible syndrome of <br />
                                            involuntary dyskinetic movements, may develop in patients treated with <br />
                                            antipsychotic drugs. The risk of developing TD and the likelihood that it<br />
                                            will become irreversible are believed to increase as the duration of <br />
                                            treatment and total cumulative dose of antipsychotic drugs administered to <br />
                                            the patient increase. Although much less commonly, TD can develop after <br />
                                            relatively brief treatment periods at low doses or even after treatment <br />
                                            discontinuation. TD may remit, partially or completely, if antipsychotic <br />
                                            treatment is withdrawn. SEROQUEL XR should be prescribed in a manner <br />
                                            that is most likely to minimize the occurrence of TD, and discontinuation <br />
                                            should be considered if signs and symptoms of TD occur</li>
                                    </ul>
                                </li>
                            </ul>
                    </section>

                    <section data-transition="slide">
                            <ul class="weight-list">
                                <li>
                        <table class="bpd-table bpd-table-3">
                            <tr>
                                <th colspan="3" class="rounded-left-right-top">Percentage of patients with adverse<br />
reactions potentially associated with EPS<sup>1,a</sup></th>
                                </th>
                            </tr>

                            <tr class="td-smaller">
                                <td></td>
                                <td>Placebo <br />(n=160)</td>
                                <td class="cell-pink">SEROQUEL XR<br />400-800 mg/day (n=151)</td>
                            </tr>

                            <tr>
                                <td>Total EPS-related<br />
adverse reactions</td>
                                <td class=" cell-gray2">3.8%</td>
                                <td class="cell-pink2 ">6.6%</td>
                            </tr>

                            <tr>
                                <td>Dystonic event<sup>b</sup></td>
                                <td class=" cell-gray2">0%</td>
                                <td class="cell-pink2 ">0.7%</td>
                            </tr>

                            <tr>
                                <td>Parkinsonism<sup>c</sup></td>
                                <td class=" cell-gray2">1.9%</td>
                                <td class="cell-pink2 ">2.7%</td>
                            </tr>

                            <tr>
                                <td>Akathisia<sup>d</sup></td>
                                <td class=" cell-gray2">0.6%</td>
                                <td class="cell-pink2 ">1.3%</td>
                            </tr>

                            <tr>
                                <td class="rounded-left-bottom">Other extrapyramidal<br />event<sup>e</sup></td>
                                <td class=" cell-gray2">1.3%</td>
                                <td class="cell-pink2  rounded-right-bottom">2%</td>
                            </tr>
                        </table>

                        <table class='footer-notes table-information'>
                            <tr>
                                <td class='line2'><sup>a</sup></td>
                                <td>Data from a 3-week, multicenter, randomized, double-blind, placebo-controlled monotherapy
                                    <br />trial in the treatment of patients with manic or mixed episodes associated with bipolar I.
                                <br /><br />Patients with the following terms were counted in respective categories:</td>
                            </tr>

                            <tr>
                                <td><sup>b</sup></td>
                                <td>Nuchal rigidity, hypertonia, dystonia, muscle rigidity, oculogyration.</td>
                            </tr>

                            <tr>
                                <td><sup>c</sup></td>
                                <td>Cogwheel rigidity, tremor, drooling, hypokinesia.</td>
                            </tr>

                            <tr>
                                <td><sup>d</sup></td>
                                <td>Akathisia, psychomotor agitation.</td>
                            </tr>

                            <tr>
                                <td><sup>e</sup></td>
                                <td>Restlessness, extrapyramidal disorder, movement disorder.</td>
                            </tr>
                        </table>

                        </li>

                        <li>
                            <ul class="list-square list-regular">
                                <li><b>Tardive Dyskinesia (TD):</b> TD, a potentially irreversible syndrome of <br />
                                    involuntary dyskinetic movements, may develop in patients treated with <br />
                                    antipsychotic drugs. The risk of developing TD and the likelihood that it <br />
                                    will become irreversible are believed to increase as the duration of <br />
                                    treatment and total cumulative dose of antipsychotic drugs administered to <br />
                                    the patient increase. Although much less commonly, TD can develop after <br />
                                    relatively brief treatment periods at low doses or even after treatment <br />
                                    discontinuation. TD may remit, partially or completely, if antipsychotic <br />
                                    treatment is withdrawn. SEROQUEL XR should be prescribed in a manner <br />
                                    that is most likely to minimize the occurrence of TD, and discontinuation <br />
                                    should be considered if signs and symptoms of TD occur</li>
                            </ul>

                        </li>
                    </section>
                </section><!-- end section bpd eps -->

                <section id='mdd-1' data-transition="slide">
                        <section data-transition="slide">
                            <div class="slide">
                                <h3>Somnolence<sup>†</sup>
                                    <span class="tiny-title">Percent of patients with major depressive disorder who <br />
                                        reported an adverse event of somnolence<sup>†</sup></span>
                                </h3>

                                <ul class="list-content">
                                    <li><div class="mdd-chart-legend mdd-legend-1">Did not report
                                            somnolence<sup>†</sup>
                                            <h3>63%</h3></div>
                                        <div class="mdd-chart-legend mdd-legend-2">Reported
                                            somnolence<sup>†</sup>
                                            <h3>37%</h3></div>
                                        <div id="pieChart-mdd-1" class="pie-chart mdd-chart-1"></div>
                                        <h4>SEROQUEL XR 150 mg/day + AD (n=315)</h4>
                                        <ul class="pink-list list-small">
                                            <li>In two 6-week clinical trials, 37% and 43% of patients
                                                <br />taking SEROQUEL XR + AD (150 mg/day and
                                                <br />300 mg/day, respectively) reported incidence
                                                <br />of somnolence<sup>&dagger;</sup> vs 9% for placebo + AD<sup>1</sup></li>
                                        </ul>
                                    </li>

                                    <li class="second-column"><div class="mdd-chart-legend mdd-legend-1">Did not report
                                            somnolence<sup>†</sup>
                                            <h3>57%</h3></div>
                                        <div class="mdd-chart-legend mdd-legend-2">Reported
                                            somnolence<sup>†</sup>
                                            <h3>43%</h3></div>
                                        <div id="pieChart-mdd-2" class="pie-chart mdd-chart-2"></div>
                                        <h4>SEROQUEL XR 300 mg/day + AD (n=312)</h4>
                                    </li>

                                    <li class="third-column third-mdd">
                                        <ul class="pink-bullet list-big">
                                            <li>
                                                Median duration of somnolence<sup>†</sup> for
                                                <br />SEROQUEL XR was 22 days and 17 days
                                                <br />(150 mg/day + AD and 300 mg/day + AD,
                                                <br />respectively)<sup>2‡</sup></li>

                                            <li>4.8% and 8.0% of patients taking
                                                <br />SEROQUEL XR + AD (150 mg/day and
                                                <br />300 mg/day, respectively) discontinued due to
                                                <br />somnolence<sup>†</sup> vs. 0.3% for placebo + AD<sup>2</sup>

                                                <ul><li class="sub">Of the patients on SEROQUEL XR + AD who
                                                    <br />discontinued due to somnolence, the
                                                    <br />majority of patients discontinued
                                                    <br />within the first three weeks (10/15
                                                    <br />for 150 mg/day and 20/25 for 300 mg/day)<sup>2</sup>
                                                </li>
                                                </ul>


                                                </li>


                                        </ul>

                                        <table class="footer-text">
                                            <tr>
                                                <td>*</td>
                                                <td>Data combined from two 6-week, multicenter, double-blind, <br />
                                                    randomized, parallel-group, placebo-controlled adjunctive <br />
                                                    therapy trials in the treatment of patients with MDD who had <br />
                                                    an inadequate response to at least one antidepressant. <br />
                                                    Inadequate response was defined as having continued <br />
                                                    depressive symptoms for the current episode (HAM-D<sub class="hamd_sub" style="margin-top: 7px;">17</sub> &nbsp;&nbsp;&nbsp;&nbsp;total <br />
                                                    score of &ge;20) despite using an antidepressant for ≥6 weeks   <br />
                                                    at or above the minimally effective labeled dose.</td>
                                            </tr>
                                            <tr>
                                                <td><sup>†</sup></td>
                                                <td>Somnolence combines adverse reaction terms “somnolence” <br />
                                                    and “sedation.”</td>
                                            </tr>
                                            <tr>
                                                <td><sup>‡</sup></td>
                                                <td>Somnolence duration was for the cumulative incidence of  <br />
                                                    somnolence and sedation.</td>
                                            </tr>
                                        </table>
                                    </li>
                                </ul>
                            </div>

                        </section>
                    </section> <!-- end mdd somnolence -->

                    <section id='mdd-2' data-transition="slide">
                        <section data-transition="slide">
                            <div class="slide"><h3>Weight Gain</h3>
                                <p>&nbsp;</p>

                                <table class='footer-notes'>
                                    <tr>
                                        <td>*</td>
                                        <td>Data combined from two 6-week, multicenter,
                                            <br />double-blind, randomized, parallel-group,
                                            <br />placebo-controlled adjunctive therapy trials in
                                            <br />the treatment of patients with MDD who had
                                            <br />an inadequate response to at least one
                                            <br />antidepressant. Inadequate response was
                                            <br />defined as having continued depressive
                                            <br />symptoms for the current episode (HAM-D<sub class="hamd_sub" style="margin-top: 7px;">17</sub>
                                            <br />total score of ≥20) despite using an
                                            <br />antidepressant for ≥6 weeks at or above the
                                            <br />minimally effective labeled dose.</td>
                                    </tr>

                                    <tr>
                                        <td colspan='2'>&nbsp;</td>
                                    </tr>

                                    <tr>
                                        <td><sup>&dagger;</sup></td>
                                        <td>Mean baseline weight was 81.0 kg (178.2 lb)
                                            <br />for placebo + AD and 81.3 kg (178.9 lb) and
                                            <br />80.9 kg (178.0 lb) for SEROQUEL XR + AD
                                            <br />(150 mg/day and 300 mg/day, respectively).</td>
                                    </tr>
                                </table>

                                <ul class="list-weight-2">
                                    <li style="width: 600px !important;">
                                        In two 6-week clinical trials, mean change in
                                        <br>weight was +1.89 lb and +2.82 lb for patients
                                        <br>taking SEROQUEL XR + AD (150 mg/day and
                                        <br>300 mg/day, respectively) vs +0.35 lb for
                                        <br>placebo + AD<sup>1,2†</sup>
                                    </li>
                                    <li style="width: 600px !important;">
                                         No patients discontinued SEROQUEL XR due to
                                        <br>weight gain<sup>1,3</sup>
                                    </li>
                                    <li style="width: 600px !important;">
                                        3% and 7% of patients taking SEROQUEL XR +
                                        <br>AD (150 mg/day and 300 mg/day, respectively)
                                        <br>had a &ge;7% increase in body weight vs 2% with
                                        <br>placebo + AD<sup>1,4</sup>
                                    </li>
                                </ul>
                            </div>
                        </section>
                    </section><!-- end bpd weight -->

                    <section id='mdd-3' data-transition="slide">
                        <section data-transition="slide">
                            <div class="slide">
                                <h3>Extrapyramidal Symptoms (EPS)<sup>†</sup></h3>
                                <p>&nbsp;</p>

                                <table class='footer-notes'>
                                    <tr>
                                        <td>*</td>
                                        <td>Data combined from two 6-week, multicenter,
                                            <br />double-blind, randomized, parallel-group,
                                            <br />placebo-controlled adjunctive therapy trials in
                                            <br />the treatment of patients with MDD who had
                                            <br />an inadequate response to at least one
                                            <br />antidepressant. Inadequate response was
                                            <br />defined as having continued depressive
                                            <br />symptoms for the current episode (HAM-D<sub>17</sub>
                                            <br />total score of ≥20) despite using an
                                            <br />antidepressant for ≥6 weeks at or above the
                                            <br />minimally effective labeled dose.</td>
                                    </tr>

									<tr>
                                        <td colspan='2'>&nbsp;</td>
                                    </tr>

                                    <tr>
                                        <td class='text_align_right'><sup>&dagger;</sup></td>
                                        <td>Extrapyramidal symptoms include the terms:
                                            <br />muscle spasms, akathisia, cogwheel rigidity,
                                            <br />drooling, dyskinesia, extrapyramidal disorder,
                                            <br />hypertonia, hypokinesia, psychomotor
                                            <br />hyperactivity, restlessness, and tremor.</td>
                                    </tr>
                                </table>

                                <ul>
                                    <li style="width: 600px !important;">In two 6-week clinical trials, incidence of EPS was
                                        <br />5.1% with SEROQUEL XR (150 mg/day + AD and
                                        <br />300 mg/day + AD) vs 4.2% for the placebo group<sup>1*</sup></li>
                                    <li style="width: 600px !important;">No patients discontinued SEROQUEL XR due to EPS<sup>2,3</sup> </li>
                                </ul>
                            </div>
                        </section>
                    </section><!-- end bpd eps -->

            </div><!-- end slides -->

        </div><!-- end tabs-bpd -->

    </div><!-- end tabs-container -->

</div><!--end main content -->

<a id="next-slide" href='#' title='Go to' class='button-down'></a>
<script type="text/javascript" src="../shared/assets/js/jquery.drawPieChart.js"></script>
<script type="text/javascript" src="../shared/assets/js/reveal.js"></script>
<script type="text/javascript">
    $(document).ready(function () {
        $('#next-slide').css('display', 'block');
        Reveal.initialize({
            touch: true,
            controls: false,
            progress: false,
            minScale: 1,
            maxScale: 1
        });

        $("#pieChart-bpd-1").drawPieChart([
            {title: "", value: 48, color: "#eb5aa1"},
            {title: "", value: 52, color: "#96989b"},
        ]);

        $("#pieChart-bpd-2").drawPieChart([
            {title: "", value: 13, color: "#96989b"},
            {title: "", value: 87, color: "#eb5aa1"},
        ]);

        $("#pieChart-mdd-1").drawPieChart([
            {title: "", value: 37, color: "#96989b"},
            {title: "", value: 63, color: "#eb5aa1"},
        ]);

        $("#pieChart-mdd-2").drawPieChart([
            {title: "", value: 43, color: "#96989b"},
            {title: "", value: 57, color: "#eb5aa1"},
        ]);
        $('#ref').attr('rel', 'patient-popup-4');
        Reveal.addEventListener('slidechanged', function (  ) {
            var currentY = Reveal.getIndices().v;
            var currentX = Reveal.getIndices().h;

            for (i = 1; i <= 3; i++) {
                $('#tbpd-' + i).removeClass('active');
            }
            for (i = 1; i <= 3; i++) {
                $('#tmdd-' + i).removeClass('active');
            }

            currentTitle = '';

            switch (currentX) {
                case 0:
                    switch (currentY) {
                        case 0:
                            currentTitle = 'Adverse reactions observed in the bipolar depression trial with SEROQUEL XR*';
                            $('#next-slide').css('display', 'block');
                            $('#ref').attr('rel', 'patient-popup-4');
                            break;
                        case 1:
                            currentTitle = 'Somnolence profile of SEROQUEL XR as monotherapy';
                            $('#next-slide').css('display', 'none');
                            $('#ref').attr('rel', 'patient-popup-5');
                            break;
                    }
                    $('#tbpd-1').addClass('active');
                    break;
                case 1:
                    $('#tbpd-2').addClass('active');
                    $('#next-slide').css('display', 'block');

                    switch (currentY) {
                        case 0:
                            currentTitle = 'Adverse reactions observed in the bipolar depression trial with SEROQUEL XR*';
                            $('#next-slide').css('display', 'block');
                             $('#ref').attr('rel', 'patient-popup-6');
                            break;
                        case 1:
                            currentTitle = 'Short-term weight gain with SEROQUEL XR as monotherapy for bipolar disorder<sup>1</sup>';
                            $('#next-slide').css('display', 'block');
                             $('#ref').attr('rel', 'patient-popup-7');
                            break;

                        case 2:
                            currentTitle = 'Weight change by BMI category with SEROQUEL XR as monotherapy for acute <br>bipolar disorder<sup>1</sup>';
                            $('#next-slide').css('display', 'none');
                             $('#ref').attr('rel', 'patient-popup-8');
                            break;
                    }
                    break;

                case 2:
                    $('#tbpd-3').addClass('active');
                    switch (currentY) {
                        case 0:
                            currentTitle = 'Adverse reactions observed in the bipolar depression trial with SEROQUEL XR*';
                            $('#ref').attr('rel', 'patient-popup-9');
                            break;
                        case 1:
                            currentTitle = 'Extrapyramidal symptom (EPS) adverse reactions of SEROQUEL XR <br>in acute depressive episodes of bipolar disorder<sup>1</sup>';
                            $('#next-slide').css('display', 'block');
                            $('#ref').attr('rel', 'patient-popup-10');
                            break;

                        case 2:
                            currentTitle = 'Extrapyramidal symptom (EPS) adverse reactions of SEROQUEL XR <br> in acute manic episodes of bipolar disorder<sup>1</sup>';
                            $('#next-slide').css('display', 'none');
                            $('#ref').attr('rel', 'patient-popup-10');
                            break;
                    }
                    $('#mdd-navbar').addClass('hidden');
                    $('#bpd-navbar').removeClass('hidden');
                    break;

                case 3:
                    currentTitle = 'Adverse reactions observed in clinical trials of SEROQUEL XR <br /> as adjunct therapy for major depressive disorder*';
                    $('#mdd-navbar').removeClass('hidden');
                    $('#bpd-navbar').addClass('hidden');
                    $('#tmdd-1').addClass('active');
                    $('#next-slide').css('display', 'none');
                    $('#ref').attr('rel', 'patient-popup-1');
                    break;

                case 4:
                    currentTitle = 'Adverse reactions observed in clinical trials of SEROQUEL XR <br /> as adjunct therapy for major depressive disorder*';
                    $('#tmdd-2').addClass('active');
                    $('#next-slide').css('display', 'none');
                    $('#ref').attr('rel', 'patient-popup-2');
                    break;

                case 5:
                    currentTitle = 'Adverse reactions observed in clinical trials of SEROQUEL XR <br /> as adjunct therapy for major depressive disorder*';
                    $('#tmdd-3').addClass('active');
                    $('#next-slide').css('display', 'none');
                    $('#ref').attr('rel', 'patient-popup-3');
                    break;
            }

            $('#title-page').html( currentTitle );
        });

        $('#next-slide').on('click', function (e) {
            e.preventDefault();
            Reveal.next();

        });
        $( "#kglbs" ).click(function() {
          $( "#kg_table" ).toggle();
        });
    });
</script>

<script>

    $(document).ready(function () {


    Reveal.addEventListener('ready', function (event) {
        checkForDeepLink.then(function(result){

        //Make sure it works
//        console.log('Deep Link: ' + deeplink);

        //Do something with the link
        switch(result) {
            case 'tol_mdd_set':
                $('#bpd-navbar').addClass('hidden');
                $('#mdd-navbar').removeClass('hidden');
                for (i = 1; i <= 3; i++) {
                    $('#tmdd-' + i).removeClass('active');
                }
                $('#tmdd-1').addClass('active');
                $('#title-gray').html('SEROQUEL XR Tolerability in MDD');
                $('#title-bpd').addClass('hidden');
                $('#title-mdd').removeClass('hidden');
                Reveal.slide( 3, 1 );
            break;
            case 'tol_weight_set':
                Reveal.slide( 1,0,0);
            break;
            case 'tol_eps_set':
                Reveal.slide( 2,0,0);
            break;
    }

    });    });  });



</script>


</div>
            </div>
        </div>

        
<link rel="stylesheet" href="../shared/assets/css/footer.css">


<div id="footer_main" class='s-footer'>
    <div class="content">
        <p><b>Important Safety Information About SEROQUEL XR&reg; (quetiapine fumarate)</b>
            <br>Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis
            <br>treated with antipsychotic drugs are at an increased risk of death. SEROQUEL XR is not approved for the treatment of patients
            <br>with dementia-related psychosis. &nbsp;<a title='MORE' href='#' class='btn-open' rel='patient-popup-ISI'><u>MORE</u></a><br />
            <i>Please read Important Safety Information and</i> <a  class="pi_ital" href='#' onclick="navigateTo('US-SXR-CNS-PI')" title='Prescribing Information'><u>Prescribing Information</u></a>, <i>including Boxed WARNINGS</i>.</p>
    </div>

    <div class='footer-right-content'>
        <a class="logo-seroquel" href='#' title='Once daily - SEROQUEL XR - quetiapine fumarate - extended-release tablets'><img src="../shared/assets/img/logo-seroquel.png" /></a>
        <ul>
            <li><a id='isi' href="#" title="ISI"  class='btn-open' rel='patient-popup-ISI'>ISI</a></li>
            <li><a id='pi' href="#" title="PI" onclick="navigateTo('US-SXR-CNS-PI')">PI</a></li>
            <li><a id='ref' href="#" title="REF" class='btn-open' rel='patient-popup'>REF</a></li>
        </ul>
    </div>
</div>

<div id="dynamicNav">&nbsp;</div>

    </body>
        <script type="text/javascript" src="../shared/assets/js/veeva-library-4.0.js"></script>
        <script type="text/javascript" src="../shared/assets/js/veeva_helper.js"></script>
        <script type="text/javascript" src="../shared/assets/js/veeva_boilerplate.js"></script>
        <script type="text/javascript" src="../shared/assets/js/reveal.js"></script>
        <script type="text/javascript" src="../shared/assets/js/main.js"></script>
        <script type="text/javascript" src="../shared/assets/js/fastclick.min.js"></script>
        <script type="text/javascript" src="../shared/assets/js/classie.js"></script>
        <script type="text/javascript" src="../shared/assets/js/sidebarEffects.js"></script>
        <script type="text/javascript" src="../shared/assets/js/iscroll5.js"></script>
        <script type="text/javascript" src="../shared/assets/js/deviceOrientation.js"></script>
        <script>

            if ('addEventListener' in document) {
                document.addEventListener('DOMContentLoaded', function() {
                    FastClick.attach(document.body);
                }, false);
            }

            $.get( "../shared/partials/toolkit.html", function( data ) {
                $('#dynamicNav').html(data);
                setupiRepNavigation();
                console.log( "Dynamic load of TOOLKIT was performed." );
            });

    	</script>
</html>

<style>
    #patient-popup-5 {
        top: 332px;
    }
	.bpd-table-4 .cell-pink2 {
		font-family: HelveticaNeue, 'Helvetica Neue', Helvetica, Arial, sans-serif;
	}
    .tolerability-mdd #mdd-3 .footer-notes td {
        font-size: 13px !important;
    }
</style>



